TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* With a diagnosis of CD20-expressing B-cell malignancy of any histologic type or grade for whom non-myeloablative allogeneic transplant is considered an appropriate treatment option~* Who are enrolled on a non-myeloablative allogeneic HCT protocol employing total-body irradiation (TBI)-based conditioning of =\< 4.5 Gy, with or without fludarabine; this protocol may be used as an adjunct to the allogeneic arm of a tandem autologous/allogeneic transplant protocol, provided the allogeneic conditioning meets the above criteria~* Receiving unmodified peripheral blood mononuclear cell graft products~* With an appropriate related or unrelated donor; human leukocyte antigen (HLA)-haploidentical donors are excluded~* Able to give informed consent (if \>= 18 years of age), or with a legal guardian capable of giving consent (if \< 18 years of age)~Exclusion Criteria:~* Ineligible for non-myeloablative allogeneic HCT~* Receiving an HLA-haploidentical allograft~* Who are fertile but unwilling to use contraception during and for at least 12 months after HCT~* Females who are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (rituximab pre- and post-transplant) (Type: EXPERIMENTAL): Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Subject aged between 18 and 57 years (i.e., less than 60 at the last vaccination)~* For woman of child-bearing potential, negative urine pregnancy test at V#01~* Use of effective contraception prior to and during the trial~* Subject available during the trial period~* Subject able to read and understand the informed consent form~* Informed consent form signed and dated by the subject prior to any protocol-required intervention (and Visit 05 and Visit 07, respectively).~Exclusion Criteria :~* Self-reported allergy to egg proteins, chick proteins, or any of the constituents of the vaccine, in particular, neomycin, formaldehyde, and octoxinol 9~* Acute febrile disease within the 72 hours preceding V#01, or axillary temperature \>37.5°C the day of inclusion, prior to vaccination (\>37.0°C Czech Republic)~* Subject with an aggravation of existing chronic illness (heart disease, respiratory disease, etc.)~* Vaccination against influenza within the 6 months preceding V#01~* Any vaccination within the 28 days preceding V#01 or scheduled between V#01 and V#02~* Breast-feeding~* Immunosuppressive therapy including long term systemic corticotherapy (20 mg/day of prednisolone or equivalent for \>2 weeks) or cancer therapy within the month preceding V#01 or ongoing~* Immunoglobulin injection within the 3 months preceding V#01~* Subject taking part or planned to take part in another clinical trial (3 months before and through the trial duration)~* Subject having received extracted pituitary hormones~* Subjects who participated in the GID01 study (Lithuanian centers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 57 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Amnestic MCI, as defined by a Clinical Dementia Rating Scale score of .5.~2. High cardiovascular risk defined as at least one of the following:~   * 7.5 percentile risk or higher using ASCVD risk calculator~  * Myocardial Infarction more than 6 months ago~  * Diabetes~  * Taking medication for blood pressure \> 140/90 blood pressure~  * Taking medication for lyperlipidemia LDL \>160~3. Sufficient English proficiency and the 8th grade or higher reading level as determined by the word reading subtest of the Wide Range Achievement Test-IV (this criterion is necessary in order to ensure ability to participate in MET, which involves reading and writing and has a Flesch-Kinkaid school equivalency of 7th grade)~4. Capacity to provide informed consent~Exclusion Criteria:~1. History of psychosis, bipolar disorder, alcohol/ drug dependence, or neurological disorder~2. Recent (within three months) surgery, anticipated surgery within next year, or unstable medical condition~3. Any disability preventing participation in MET or KK+KY (e.g., severe visual or hearing impairment)~4. Insufficient English proficiency to participate in either MET or KK+KY~5. Diagnosis of dementia~6. Mini Mental Health Examination score of 23 or below~7. Currently taking any psychoactive medication~8. Participation in a psychotherapy that involves cognitive training~9. Practice of Kundalini Yoga or Kirtan Kriya within the past year~10. Myocardial Infarction within the past 6 months

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Memory Training (Type: ACTIVE_COMPARATOR): Group memory training will be administered for amnestic mild cognitive impairment (MCI)
- Kundalini yoga and meditation (Type: EXPERIMENTAL): Participants will engage in weekly yoga classes and daily 12 minute meditation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects between the ages of 19 and 55 years, both inclusive~* Body Mass Index (BMI) between 18.0 and 29.9 kg/m2 (both inclusive) and a body weight ≥ 50 kg~Exclusion Criteria:~* Subject is a female.~* Clinically significant allergic reactions, hypersensitivity~* A disease classed as significant by the Investigator~* Non-healing wound, ulcer, bone fracture, a major surgical procedure, significant traumatic injury~* Any malignancy~* Undergone treatment with an investigational drug or participated in another clinical trial~* Plans to father a child or donates sperms

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P16 (Type: EXPERIMENTAL): CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
- EU-approved Avastin (Type: ACTIVE_COMPARATOR): EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
- US-licensed Avastin (Type: ACTIVE_COMPARATOR): US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Partial seizures with or without secondary generalization.~Exclusion Criteria:~* Subject has previously received iv lacosamide.~* Subject meets the withdrawal criteria for the open-label extension trial.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Conservative Versus Surgical Treatment of Appendicitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected appendicitis in patients over 18 years~Exclusion Criteria:~* Under 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Op (Type: NO_INTERVENTION): traditional surgery
- Ab (Type: EXPERIMENTAL): antibiotic treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented MCL.~* Must have received at least one prior therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤1.~* Adequate organ function as outlined in the protocol.~Exclusion Criteria:~* Major surgery, radiation therapy, or systemic therapy within 4 weeks of study enrollment.~* Prior radiation therapy to \>25% of the bone marrow (whole pelvis is 25%).~* Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PD-0332991 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6-59 months old children (male and female)~* Weight ≥ 6kg~* Uncomplicated malaria caused by P. falciparum~* Asexual parasites ≥ 2 000/µl and ≤ 200 000/µl~* Axillary temperature ≥ 37.5°C or a history of fever during last 24 hours~* Burkinabe nationality~* Permanent residence in the study area with no intention of leaving during the surveillance period~* Informed consent~Exclusion Criteria:~* Severe malaria (WHO 2000)~* Vomiting (3 or more within 24 hours before the visit)~* Any apparent significant disease, including severe malnutrition~* A history of a previous, significant adverse reaction to either of the study drugs~* Anaemia (haemoglobin \< 7 g/dl)~* Treated in the same trial before~* All modern antimalarial treatment prior to inclusion (last seven days)~* Simultaneous participation in another investigational study~* Treatment with other investigational drugs

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- artesunate, amodiaquine methylene blue (Type: ACTIVE_COMPARATOR): two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
- artesunate amodiaquine (Type: NO_INTERVENTION): The control group will receive once daily a fixed dose AS-AQ over three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old and older~* Type 2 Diabetes Mellitus according to American Diabetes Association~* Diabetic Polyneuropathy by Dyck et. al. criteria~* HbA1c \<12%~* Informed consent signed~Exclusion Criteria:~* Renal or hepatic failure~* Pregnant or breastfeeding~* Other neuropathies (alcohol-induced, radiculopathy, autoimmune, cancer-related)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): calcined magnesia 100 mg tablets once a day for 16 weeks
- ezetimibe/simvastatin (Type: ACTIVE_COMPARATOR): ezetimibe/simvastatin 10/20 mg tablets once a day for 16 weeks
- rosuvastatin (Type: ACTIVE_COMPARATOR): rosuvastatin 20 mg tablets once a day for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with prostate cancer and indicated for androgen deprivation therapy (ADT)~* Decision made to prescribe ADT prior to enrolment~* Willing and able to provide written informed consent~Exclusion Criteria:~* Participation in an interventional clinical study in which any treatment or follow-up is mandated~* Treatment with a GnRH receptor antagonist other than FIRMAGON~* Had previous or is currently under hormonal management of prostate cancer, except for subjects who have undergone therapy with curative intention where neoadjuvant/adjuvant therapy allowed for maximum 6 months. Treatment should be terminated at least 6 months prior to baseline.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FIRMAGON (Type: None): None
- GnRH Agonist (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed and active Waldenstrom's Macroglobulinemia requiring treatment.~* Ambulatory and capable of all selfcare. Up and about more than 50% of waking hours.~* Adequate organ function.~* Detectable CD20 positive of the tumor cells.~* Measurable disease as defined by a monoclonal IgM paraprotein level greater than 1000 mg/dL.~Exclusion Criteria:~* Treatment of WM within the past 28 days.~* Treatment with rituximab or alemtuzamab within the past 3 months.~* Certain heart problems, chronic or current active infection not controlled with oral antibiotics, other current cancer or within last 5 years.~* Current participation in another interventional clinical study.~* Lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception.~* Active cerebrovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Type: EXPERIMENTAL): Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosed with HCM (hypertrophied and non-dilated left ventricle in absence of systemic or other known cause), with LV wall thickness ≥ 15 mm at time of initial diagnosis or ≥ 13 mm with a positive family history of HCM.~* Age 18-70~* BMI 18-37kg/m2~* Documented LVEF ≥ 55% at the Screening visit as determined by the investigator and the investigational site's echocardiography laboratory.~* Resting LVOT gradient ≥ 30 mg Hg and post-exercise peak LVOT gradient ≥ 50 mm Hg~* NYHA functional class II or higher~Key Exclusion Criteria:~* History of sustained ventricular tachyarrhythmia.~* History of syncope with exercise within past 6 months.~* Active infection.~* Persistent atrial fibrillation or atrial fibrillation at Screening or history of paroxysmal atrial fibrillation with resting rate document \> 100bpm within 1 year of screening.~* Has QTc Fridericia (QTcF) \> 500 ms, or any other ECG abnormality considered by the investigator to pose a risk to subject safety (e.g. second degree atrioventricular block type II).~* Aortic stenosis or fixed subaortic obstruction.~* History of LV systolic dysfunction (LVEF \< 45%) at any time during their clinical course.~* History of obstructive coronary artery disease.~* History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or MyoKardia physician, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.~* Part A: Ongoing therapy with beta blockers, calcium channel blockers, or disopyramide. Subjects on any of these medications who, in the opinion of the investigator, can safely be withdrawn are eligible as long as medication is discontinued at least 14 days prior to the Screening visit.~* Part B: Ongoing therapy with calcium channel blockers or disopyramide. Subjects on any of these medications who, in the opinion of the investigator, can safely be withdrawn are eligible as long as medication is discontinued at least 14 days prior to the Screening visit.~* Prior treatment with cardiotoxic agents such as doxorubicin or similar, or current treatment with antiarrhythmic drugs that have negative inotropic activity, e.g. flecainide or propafenone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): MYK-461

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female.~* Aged 18-64 years (both inclusive) at the time of signing informed consent.~* Diagnosed with type 2 diabetes mellitus greater than equal to (≥) 180 days prior to the day of screening.~* Glycosylated haemoglobin (HbA1c) of 7.0 - 10.5 percentage (%) \[53 - 91 millimoles per mole (mmol/mol)\] (both inclusive).~* Body Mass Index (BMI) ≥ 27.0 kilograms per meter square (kg/m\^2).~* Stable daily dose(s) ≥ 90 days prior to the day of screening of any metformin formulations.~Exclusion Criteria:~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to day of screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.~* Renal impairment measured as estimated glomerular filtration rate (eGFR) value of less than (\<) 30 milliliters per minute (mL/min)/1.73 meter square (m\^2) at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide 2 mg (Type: EXPERIMENTAL): Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.
- Semaglutide placebo 2 mg (Type: PLACEBO_COMPARATOR): Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.
- Semaglutide 8 mg (Type: EXPERIMENTAL): Participants will receive once-weekly semaglutide 8 mg s.c. injection.
- Semaglutide placebo 8 mg (Type: PLACEBO_COMPARATOR): Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.
- Semaglutide 16 mg (Type: EXPERIMENTAL): Participants will receive once-weekly semaglutide 16 mg s.c. injection.
- Semaglutide placebo 16 mg (Type: PLACEBO_COMPARATOR): Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete